New Gastrointestinal Stromal Tumor Drug 'Qinlock' Approved in Korea… Urgent Need to Address Medical Vacuum
Published
The Ministry of Food and Drug Safety announced on the 16th that it has approved the domestic use of the new gastrointestinal stromal tumor (GIST) treatment 'Qinlock' (ingredient name: ripretinib). This approval is expected to provide new treatment opportunities for patients who have not responded to existing therapies or have faced difficulties due to side effects.
Gastrointestinal stromal tumor is a type of rare cancer that occurs in the walls of the digestive tract, such as the stomach or small intestine. Qinlock works by inhibiting specific enzymes involved in the growth of cancer cells and is expected to help extend the survival period of patients, particularly as a fourth-line treatment.
Meanwhile, in the political sphere, there have been ongoing efforts to resolve the national turmoil that followed the passage of the impeachment motion against President Yoon Suk Yeol. In particular, there are growing calls for urgent measures to fill the void in the medical field and protect the public's right to health.
Political circles, led by the opposition party, are working closely with relevant ministries to resolve the medical crisis. The medical community is also focusing its efforts on normalizing medical services and maintaining the essential healthcare system to minimize harm to patients.
The government stated that it will continue to implement public health policies, such as this new drug approval, without setbacks, while doing its utmost to resolve social anxiety and restore stability to the medical field. The public hopes that the political and medical turmoil will be brought to an end as soon as possible.
Sources: 코리아헬스로그
More South Korea news
- Digital TVET master's program launches in South Korea
- Gyeongbuk health group donates 100 boxes of grapes to children
- US Big Tech Pursues Multi-Trillion Won Investments in South Korean Data Centers Amid Uncertainty
- KB Insurance to Hold Open Recruitment for New Employees in Second Half of 2026
- Kolmar Korea Wins CES Beauty Tech Best Innovation Award for Second Straight Year, Setting World First
- China Closes In on Korea's Core LNG Carrier Market, Expanding from Mega-Vessels to Equipment
- China's Rapid Technological Development: South Korea Must Change Its Regulations and Labor System
- Ambassador Michelle Steel: American Companies Operating in Korea Should Compete in a Fair Environment